Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy

Gynecologic Oncology

Volumn 87, Issue 1, 2002, Pages 1-7

  Schilder, Jeanne M ^a,j   Thompson, Amy M ^a   DePriest, Paul D ^a   Ueland, Frederick R ^a   Cibull, Michael L ^a   Kryscio, Richard J ^a   Modesitt, Susan C ^b   Lu, Karen H ^b   Geisler, John P ^c   Higgins, Robert V ^d   Magtibay, Paul M ^e   Cohn, David E ^f   Powell, Matthew A ^g   Chu, Christina ^h   Stehman, Frederick B ⁱ   Van Nagell, John ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d CAROLINAS MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

^f THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j INDIANA UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; MELPHALAN; PACLITAXEL;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CELL TYPE; CONGENITAL MALFORMATION; CONTROLLED STUDY; DELIVERY; FEMALE; FEMALE FERTILITY; FOLLOW UP; HISTOLOGY; HUMAN; HYSTERECTOMY; LAPAROTOMY; LONG TERM CARE; LUNG; MAJOR CLINICAL STUDY; OVARIECTOMY; OVARY; OVARY CANCER; OVARY TUMOR; PERITONEUM; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REPRODUCTION; RETROSPECTIVE STUDY; SPONTANEOUS ABORTION; TREATMENT OUTCOME; TUMOR RECURRENCE;

EID: 0036919922     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2002.6805     Document Type: Article

References (51)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2001;51:15-36.
2. Duska LR, Chang Y, Flynn CE, Chen AH, Goodman A, Fuller AF, Nikrui N. Epithelial ovarian carcinoma in the reproductive age group. Cancer 1999;85:2623-29.
3. Plaxe SC, Braly PS, Freddo JL, McClay E, Kirmani S, Howell SB. Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer. Obstet Gynecol 1993;81:651-54.
4. Rodriguez M, Nguyen HN, Averette HE, Steren AJ, Penalver MA, Harrison T, et al. National survey of ovarian carcinoma XII. Epithelial ovarian malignancies in women less than or equal to 25 years of age. Cancer 1994;73:1245-50.
5. Swerenton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N, Boyes DA. Ovarian carcinoma: A multivariate analysis of prognostic factors. Obstet Gynecol 1985;65:264-70.
6. Smedley H, Sikora K. Age as a prognostic factor in epithelial ovarian carcinoma. Br J Obstet Gynaecol 1985;92:839-42.
7. Scully RE. Recent progress in ovarian cancer. Hum Pathol 1970;1:73-98.
8. DiSaia PJ. Fertility-sparing treatment of patients with ovarian cancer. Comprehens Ther 1990;16:35-42.
9. Julian CG, Woodruff JD. The biologic behavior of low-grade papillary serous carcinoma of the ovary. Obstet Gynecol 1971;40:860-67.
10. Bostwick DG, Tazelaar HD, Ballon SC, Hendrickson MR, Kempson RL. Ovarian epithelial tumors of borderline malignancy. Cancer 1986;58:2052-65.
11. Gallion HH, van Nagell JR, Donaldson ES, Powell DE. Ovarian dysgerminoma. Report of seven cases and review of the literature. Am J Obstet Gynecol 1988;158:591-95.
12. Lim-Tam SK, Cajigas HE, Scully RE. Ovarian cystectomy for serous borderline tumors. A follow-up study of 35 cases. Obstet Gynecol 1988;72:775-81.
13. Casey AC, Bell DA, Lage JM, Fuller AF, Nikrui N, Rice LW. Epithelial ovarian tumors of borderline malignancy: Long-term follow-up. Gynecol Oncol 1993;50:316-22.
14. Casey AC, Bhodauria S, Shapter A, Nieberg R, Berek JS, Farias-Eisner R. Dysgerminoma: The role of conservative surgery. Gynecol Oncol 1996;63:352-57.
15. Stier EA, Karakat RR, Curtin JP, Brown CL, Jones WB, Hoskins WJ. Laparotomy to complete staging of presumed early ovarian cancer. Obstet Gynecol 1996;87:737-40.
16. Brewer M, Gershenson DM, Herzog CE, Mitchell MF, Silva EG, Wharton JT. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 1999;17:2670-75.
17. McHale MT, DiSaia PJ. Fertility-sparing treatment of patients with ovarian cancer. Comprehens Ther 1999;25:144-50.
18. Low JJH, Perrin LC, Crandon AJ, Hacker NF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. Cancer 2000;89:391-98.
19. Morice P, Camatte S, El-Hassan J, Lhomme C, Duvillard P, Castaigne D. Clinical outcomes and fertility results after conservative treatment for ovarian borderline tumor. Fertil Steril 2001;75:92-96.
20. Miyazaki T, Tomoda Y, Ohta M, Kano T, Mizuno K, Sakakibara K. Preservation of ovarian function and reproductive ability in patients with malignant ovarian tumors. Gynecol Oncol 1988;30:329-41.
21. Raspagliesi F, Fontanelli R, Paladini D, di Re EM. Conservative surgery in high-risk epithelial ovarian carcinoma. J Am Col Surg 1997;185:457-60.
22. Gonzalez-Lira G, Escudero-Le Los Rios P, Salazar-Martinez E, Lazcano-Ponce EC. Conservative surgery for ovarian cancer and effect on fertility. Int J Gynaecol Obstet 1997;56:155-62.
23. Columbo N, Chiari S, Maggioni A, Bocciolone L, Torri V, Mangioni C. Controversial issues in the management of early epithelial ovarian cancer: Conservative surgery and role of adjuvant therapy. Gynecol Oncol 1994;55:457-51.
24. Zanetta G, Chiari S, Rota S, Bratina G, Maneo A, Torri V, Mangioni C. Conservative surgery for stage I ovarian carcinoma in women of child-bearing age. Br J Obstet Gynaecol 1997;104:1030-35.
25. Brown CL, Dharmendra B, Barakat R. Preserving fertility in patients with epithelial ovarian cancer: The role of conservative surgery in treatment of early stage disease. Gynecol Oncol 2000;76:40.
26. Morice P, Wicart-Poque F, Rey A, El-Hassan J, Pautier P, Lhomme C, deCrevoisier R, Haie-Meder C, Duvillard P, Castaigne D. Results of conservative treatment in epithelial ovarian carcinoma. Cancer 2001;92:2412-18.
27. National Institutes of Health Consensus Development Conference. Statement on cervical cancer. Gynecol Oncol 1997;66:351-61.
28. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995;333:1456-61.
29. 2 squamous cell carcinoma of the vulva. Gynecol Oncol 1994;55:41-46.
30. Menczer J. A trend toward more conservative surgery in gynecologic oncology. Obstet Gynecol Surv 1995;41:628-36.
31. Plante M. Fertility preservation in the management of gynecologic cancers. Curr Opin Oncol 2000;12:497-507.
32. Piver MS, Barlow JJ, Lele SB. Incidence of subclinical metastasis in stage I and II ovarian carcinoma. Obstet Gynecol 1978;52:100-04.
33. Chen SS, Lee L. Incidence of para-aortic and pelvic lymph node metastases in epithelial carcinoma of the ovary. Gynecol Oncol 1983;15:95-100.
34. Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 1991;40:103-06.
35. Cass I, Li AJ, Runowicz CD, Fields AL, Goldberg GL, Leuchter RS, Lagasse LD, Kartan BY. Patterns of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol 2001;80:56-61.
36. Kottmeier HL. Surgical management-conservative surgery. In: Gentil F, Junqueria AC, editors. Ovarian Cancer. Vol. 2. New York: Springer Verlag, 1968.
37. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, Major F. Adjuvant therapy in stage I and stage II epithelial ovarian cancer: Results of two prospective randomized trials. N Engl J Med 1990;322:1021-27.
38. National Institutes of Health Consensus Development Panel on Ovarian Cancer. National Institutes of Health Consensus Conference. Ovarian cancer. Screening, treatment and follow-up. J Am Med Assoc 1995;8:491-97.
39. Le T, Krepart GV, Lotocki RJ, Heywood MS. Clinically apparent early stage invasive epithelial ovarian carcinoma: Should all be treated similarly? Gynecol Oncol 1999;74:252-54.
40. Young RC. Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer. Semin Oncol 2000;27:8-10.
41. O'Brien ME, Schofield JB, Tan S, Fryatt I, Fisher C, Wiltshaw E. Clear cell epithelial ovarian cancer (mesonephroid): Bad prognosis only in early stages. Gynecol Oncol 1993;49:250-54.
42. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K. Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-89.
43. Hogberg T, Glimelius B, Nguyen P. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 2001;40:340-60.
44. Andrieu JM, Ochoa-Molina ME. Menstrual cycle, pregnancies and offspring before and after MOPP therapy for Hodgkin's disease. Cancer 1983;52:435-38.
45. Gershenson DM. Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. J Clin Oncol 1988;5:270-75.
46. Kanazawa K, Suzuki T, Sakumoto K. Treatment of malignant ovarian germ cell tumors with preservation of fertility: Reproductive performance after persistent remission. Am J Clin Oncol 2000;23:244-48.
47. Averette HE, Boike GM, Jarrell MA. Effects of cancer chemotherapy on gonadal function and reproductive capacity. Ca J Clin 1990;40:199-209.
48. Ahmed FY, Wiltshaw E, A'Hern RP, Nicol B, Shepherd J, Blake P, Fisher C, Gore ME. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 1996;14:2968-75.
49. Young RC, Pecorelli S. Management of early ovarian cancer. Semin Oncol 1998;25:335-39.
50. Pecorelli S, Odicino F, Maisonneuve P, Creasman W, Shepard J, Sideri M, et al. Carcinoma of the ovary. Annual report on the results of treatment of gynaecological cancer. J Epidemiol Biostat 1998;3:75-102.
51. Vergote I, Fyles A, Bertelsen K, Einhom N, Sevelda P, Kaem J, et al. Analysis of prognostic factors in 1287 patients with FIGO stage I invasive ovarian cancer. Proc Am Soc Clin Oncol 1998;34:1389.